Rafael Holdings has submitted a New Drug Application to the FDA for remibetadex (Trappsol Cyclo) to treat Niemann-Pick Disease Type C, a rare and fatal genetic disorder. The application is supported by Phase 3 trial data showing slowed disease progression and survival benefits, despite not meeting the primary endpoint statistically. The drug has received Orphan Drug, Fast Track, and Rare Pediatric Disease designations, potentially qualifying for a Priority Review Voucher if approved. The FDA will decide on filing and review status within 60 days, with Rafael preparing for a possible commercial launch pending approval.
Rafael Holdings' submission of a New Drug Application to the FDA for Trappsol® Cyclo™ coincides with a mixed day for health stocks on Pluang. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 29, 2026 17:11 WIB: out of 150 priced US health stocks, 86 rose and 57 fell. Notable movers include TDOC (Teladoc Health Inc) up 10.47% at USD 7.60 with a typical hold time of 39 days, IOVA (Iovance Biotherapeutics Inc.) down 100% sell activity at USD 16.12, and BFLY (Butterfly Network Inc.) up 6.53% at USD 8.32 with a 14-day hold time.
The inaugural SportsTech Breakthrough Awards recognized leading companies and technologies advancing sports technology globally. Winners span categories like athlete performance, wearables, AI analytics, fan engagement, and smart stadium solutions, h...
The global Industrial Control System (ICS) Security Market is projected to grow from $17.91 billion in 2026 to $38.48 billion by 2031, at a CAGR of 16.5%. This growth is driven by rising cyberattacks targeting critical infrastructure and the increasi...
AdvantageLumber.com has introduced Sketch-A-Deck, a free online software that simplifies deck design for homeowners and contractors. The tool allows users to draw custom deck layouts, attach them to their homes, and generate build-ready plans with de...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
